Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD) By Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) And Segment Forecasts, 2013 - 2024

Published: Nov, 2016 | Pages: 110 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The genitourinary drugs market is expected to reach USD 29.7 billion by 2024, according to a new study by Grand View Research, Inc. This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.

In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.

Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.

Further Key Findings from the Study Suggest:

Prostate cancer held the largest share of the indication segment in 2015 owing to the rising global incidence of the condition. In addition, advances in proteomics technology and improved screening and diagnostic procedures are presumed to be responsible for the dominant share.

Other products segment captured the majority share of 44.8% in the application segment in 2015. This is attributed to the numerous products launched by the major market players, which is responsible in widening the growth platform. For instance, in January 2016, ProstaPlast presented transdermal urological plasters in Europe, which demonstrated its clinical efficacy in reducing urinary problems in majority of the patients.

In 2015, North America dominated the global genitourinary drugs vertical with a share of over 42.6%. The dominant share is attributable to the high disease burden present in this region, thus driving the inclination of researchers and healthcare professionals toward advanced formulation technologies, which is anticipated to widen the growth scope for this sector.

Asia Pacific is expected to witness a lucrative CAGR of over 5.6% during the forecast period. The exponential growth rate can be attributed to the rising healthcare spending and the improving infrastructure quality of clinical research and manufacturing facilities owing to the initiatives of the key vertical players.

The prominent participants are employing new product development and collaborative strategies to capture greater market share and increase their presence in this sector. For instance, in March 2015, Novartis AG further enhanced its cancer immunotherapy research initiative through collaboration with Aduro Biotech to increase its activities toward discovery and development in next generation cancer immunotherapy.

Table of Content

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Driver Analysis
4.2.1. Increasing number of pipeline drugs
4.2.2. Growing prevalence of genitourinary disorders
4.3. Market Restraint Analysis
4.3.1. Increasing advent of counterfeit drugs
4.3.2. Growing generics drug competition
4.3.3. High number of patent expirations in the coming years
4.4. Penetration & Growth Prospect Mapping
4.5. Genitourinary Drugs - SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Indication Estimates & Trend Analysis
5.1. Genitourinary Drugs Market: Indication Movement Analysis
5.2. Prostate Cancer
5.2.1. Prostate cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.3. Ovarian Cancer
5.3.1. Ovarian cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.4. Bladder Cancer
5.4.1. Bladder cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.5. Cervical Cancer
5.5.1. Cervical cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.6. Renal Cancer
5.6.1. Renal cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.7. Erectile Dysfunction
5.7.1. Erectile dysfunction market estimates and forecasts, 2013 - 2024 (USD Million)
5.8. Urinary Tract Infections
5.8.1. Urinary tract infections market estimates and forecasts, 2013 - 2024 (USD Million)
5.9. Urinary Incontinence & Overactive Bladder
5.9.1. Urinary incontinence & overactive bladder market estimates and forecasts, 2013 - 2024 (USD Million)
5.10. Sexually Transmitted Diseases
5.10.1. Sexually transmitted diseases market estimates and forecasts, 2013 - 2024 (USD Million)
5.11. Interstitial Cystitis
5.11.1. Interstitial cystitis market estimates and forecasts, 2013 - 2024 (USD Million)
5.12. Hematuria
5.12.1. Hematuria market estimates and forecasts, 2013 - 2024 (USD Million)
5.13. Benign Prostatic Hyperplasia
5.13.1. Benign Prostatic Hyperplasia market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6. Market Categorization 2: Product Estimates & Trend Analysis
6.1. Genitourinary Drugs Market: Product Movement Analysis
6.2. Urologicals
6.2.1. Urologicals market estimates and forecasts, 2013 - 2024 (USD Million)
6.3. Hormonal Therapy Drugs
6.3.1. Hormonal therapy drugs market estimates and forecasts, 2013 - 2024 (USD Million)
6.4. Gynecological
6.4.1. Gynecological market estimates and forecasts, 2013 - 2024 (USD Million)
6.5. Anti-infectives
6.5.1. Anti-infectives market estimates and forecasts, 2013 - 2024 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 7. Market Categorization 3: Regional Estimates & Trend Analysis, By Indication & Product
7.1. Genitourinary Drugs Market Share By Region, 2015 & 2024
7.2. North America
7.2.1. North America market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.2.1.1. U.S. market estimates and forecasts
7.2.1.2. Canada market estimates and forecasts
7.2.2. North America market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.2.2.1. U.S. market estimates and forecasts
7.2.2.2. Canada market estimates and forecasts
7.3. Europe
7.3.1. Europe market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.3.1.1. UK market estimates and forecasts
7.3.1.2. Germany market estimates and forecasts
7.3.2. Europe market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.3.2.1. UK market estimates and forecasts
7.3.2.2. Germany market estimates and forecasts
7.4. Asia Pacific
7.4.1. Asia Pacific market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.4.1.1. Japan market estimates and forecasts
7.4.1.2. China market estimates and forecasts
7.4.1.3. India market estimates and forecasts
7.4.2. Asia Pacific market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.4.2.1. Japan market estimates and forecasts
7.4.2.2. China market estimates and forecasts
7.4.2.3. India market estimates and forecasts
7.5. Latin America
7.5.1. Latin America market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.5.1.1. Brazil market estimates and forecasts
7.5.1.2. Mexico market estimates and forecasts
7.5.2. Latin America market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.5.2.1. Brazil market estimates and forecasts
7.5.2.2. Mexico market estimates and forecasts
7.6. MEA
7.6.1. MEA market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.6.1.1. South Africa market estimates and forecasts
7.6.2. MEA market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.6.2.1. South Africa market estimates and forecasts
Chapter 8. Competitive Landscape
8.1. Market Participation Categorization
8.2. Company Profiles
8.2.1. Abbott
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Bristol-Myers Squibb Co.
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Novartis AG
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Genentech, Inc.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. F. Hoffmann-La Roche Ltd
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Ionis Pharmaceuticals, Inc.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Eli Lilly and Company
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Merck & Co., Inc.
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Pfizer, Inc.
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. AstraZeneca
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. GlaxoSmithKline
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Teva Pharmaceutical Industries Ltd.
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Bayer AG
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. Allergan
8.2.14.1. Company overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives
8.2.15. Antares Pharma
8.2.15.1. Company overview
8.2.15.2. Financial performance
8.2.15.3. Product benchmarking
8.2.15.4. Strategic initiatives

List of Tables


TABLE 1 Country share estimation
TABLE 2 North America genitourinary drugs market, by indication, 2013 - 2024 (USD Million)
TABLE 3 North America genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 4 U.S. genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 5 U.S. genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 6 Canada genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 7 Canada genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 8 Europe genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 9 Europe genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 10 Germany genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 11 Germany genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 12 UK genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 13 UK genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 14 Asia Pacific genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 15 Asia Pacific genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 16 Japan genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 17 Japan genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 18 China genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 19 China genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 20 India genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 21 India genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 22 Latin America genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 23 Latin America genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 24 Brazil genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 25 Brazil genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 26 Mexico genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 27 Mexico genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 28 MEA genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 29 MEA genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 30 South Africa genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 31 South Africa genitourinary drugs market, by product, 2013 - 2024 (USD Million)